Value Sense
LBPH
Longboard Pharmaceuticals, Inc. (LBPH)
Last Price$60.00.0%
Market Cap$2,336.7M
LTM EBITDA
($87.4M)
YoY Growth
+65.3%
3Y CAGR
+44.2%
5Y CAGR
N/A
Stock quality & Intrinsic value
6/10
81.3% overvalued
LBPH
is (81.3%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Longboard Pharmaceuticals, Inc. EBITDA

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'20Dec'21Dec'22Dec'23
EBITDA
($14.4M)
($27.8M)
($44.8M)
($56.8M)
LBPH
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for LBPH and see if it's the right time to invest.
Dive in

Longboard Pharmaceuticals, Inc. (LBPH) EBITDA comparison analysis

General

LTM EBITDA

Growth

Company name

YoY growth

3Y CAGR

5Y CAGR

Longboard Pharmaceuticals, Inc. logo
Longboard Pharmaceuticals, Inc.LBPH
($87.4M)
65.3%
44.2%
N/A
Median Peer Set
$219.5M
(12.6%)
0.0%
(1.4%)
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
$4,810.3M
1.5%
(21.2%)
14.1%
Royalty Pharma plc logo
Royalty Pharma plcRPRX
$1,834.8M
2.1%
10.0%
(7.1%)
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
$1,607.4M
22.7%
32.7%
N/A
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.BMRN
$650.5M
109.7%
139.4%
82.6%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
$486.3M
(89.4%)
(45.0%)
(20.8%)
argenx SE logo
argenx SEARGX
($47.4M)
(81.7%)
N/A
(19.0%)
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
($193.0M)
(25.3%)
(33.7%)
(26.3%)
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
($212.6M)
(64.4%)
29.1%
50.0%
BioNTech SE logo
BioNTech SEBNTX
($391.5M)
N/A
N/A
20.7%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
($728.1M)
(39.9%)
(17.8%)
(2.8%)

LBPH key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
Cost of Goods Sold (COGS)0.00.00.00.0
Gross Profit
% margin
0.0
0.0%
(0.0)
0.0%
(0.0)
0.0%
(0.0)
0.0%
Operating Expenses14.427.844.856.8
Research & Development Expenses (R&D)4.619.834.643.8
Selling, General & Administrative Expenses (SG&A)9.88.110.213.0
Operating Income
% margin
(14.4)
0.0%
(27.8)
0.0%
(44.8)
0.0%
(56.8)
0.0%
Interest Income0.00.10.82.4
Interest Expense0.00.00.80.0
Pre-tax Income(14.4)(27.8)(43.9)(54.4)
Income Tax
% effective tax rate
(0.0)
0.1%
(0.1)
0.2%
(0.9)
1.9%
0.0
0.0%
Net Income
% margin
(14.4)
0.0%
(27.7)
0.0%
(43.1)
0.0%
(54.4)
0.0%
EPS(0.82)(1.62)(2.51)(2.39)
Diluted EPS(0.82)(1.62)(2.51)(2.39)
EBITDA
% margin
(14.4)
0.0%
(27.8)
0.0%
(44.8)
0.0%
(56.8)
0.0%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Longboard Pharmaceuticals, Inc.'s EBITDA?

As of today, Longboard Pharmaceuticals, Inc.'s last 12-month EBITDA is ($87.4M), based on the financial report for Sep 30, 2024 (Q3’2024).

2) What is Longboard Pharmaceuticals, Inc.'s EBITDA growth rate?

Over the last year, Longboard Pharmaceuticals, Inc.'s EBITDA growth was 65.3%. The average annual EBITDA growth rates for Longboard Pharmaceuticals, Inc. have been 71.4% over the past three years, N/A over the past five years.

3) Is Longboard Pharmaceuticals, Inc.'s EBITDA growth rate Good?

Over the last year, Longboard Pharmaceuticals, Inc.'s EBITDA growth was 65.3%, which is higher than industry growth of (0.1%). It indicates that Longboard Pharmaceuticals, Inc.'s EBITDA growth is Good.

4) How does Longboard Pharmaceuticals, Inc.'s EBITDA growth rate compare to its peers?

Over the last year, Longboard Pharmaceuticals, Inc.'s EBITDA growth was 65.3%, which is higher than peer median growth of (69.1%). The list of peers includes REGN, RPRX, UTHR, BMRN, VRTX, ARGX, ALNY, SMMT, BNTX, BGNE etc.